[go: up one dir, main page]

ECSP13013008A - Imidazopiridazinas como inhibidores de quinasa akt - Google Patents

Imidazopiridazinas como inhibidores de quinasa akt

Info

Publication number
ECSP13013008A
ECSP13013008A ECSP13013008A ECSP13013008A EC SP13013008 A ECSP13013008 A EC SP13013008A EC SP13013008 A ECSP13013008 A EC SP13013008A EC SP13013008 A ECSP13013008 A EC SP13013008A
Authority
EC
Ecuador
Prior art keywords
imidazopiridazinas
quinasa
akt inhibitors
akt
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
William J Scott
Lars Bärfacker
Hans Briem
Ulf Bömer
Andrea Hägebarth
Stuart Ince
Hartmut Rehwinkel
Oliver Politz
Roland Neuhaus
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of ECSP13013008A publication Critical patent/ECSP13013008A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Imidazopiridazinas de fórmula (I), un proceso para su producción y el uso las mismas.
ECSP13013008 2011-04-07 2013-11-04 Imidazopiridazinas como inhibidores de quinasa akt ECSP13013008A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07

Publications (1)

Publication Number Publication Date
ECSP13013008A true ECSP13013008A (es) 2013-12-31

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013008 ECSP13013008A (es) 2011-04-07 2013-11-04 Imidazopiridazinas como inhibidores de quinasa akt

Country Status (43)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PH (1) PH12013502073A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
JP5507552B2 (ja) 2008-06-16 2014-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌を処置するための化合物
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
WO2012136776A1 (en) * 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
EP2802588B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted pyrazolopyrimidines as akt kinase inhibitors
EP2802586B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
US20150328320A1 (en) * 2012-11-30 2015-11-19 Glaxosmithkline Llc Novel Pharmaceutical Composition
JP6835472B2 (ja) * 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
US20160045531A1 (en) * 2013-03-14 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
CA2936024A1 (en) * 2014-01-09 2015-07-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
MA46888A (fr) * 2016-11-28 2021-06-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246621A4 (en) 1999-12-23 2004-11-24 Nitromed Inc NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE
EP1268478B1 (en) 2000-03-31 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
JP3729343B2 (ja) 2000-04-27 2005-12-21 アステラス製薬株式会社 縮合ヘテロアリール誘導体
EP1608628A2 (en) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7579355B2 (en) 2003-04-24 2009-08-25 Merck & Co., Inc. Inhibitors of Akt activity
KR20060034303A (ko) 2003-07-30 2006-04-21 라보라토리오스 에스.에이.엘.브이.에이.티., 에스.에이. 암을 예방하고 치료하기 위한 치환된 이미다조피리미딘
DE602005026509D1 (de) 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
WO2006036395A2 (en) 2004-08-23 2006-04-06 Merck & Co., Inc. Inhibitors of akt activity
WO2006021303A1 (de) 2004-08-24 2006-03-02 Basf Aktiengesellschaft Imidazolium-methylsulfite als ausgangsverbindungen zur herstellung ionischer flüssigkeiten
AU2005316826A1 (en) 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1902056A2 (en) 2005-05-20 2008-03-26 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
EP1898903B8 (en) 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008154241A1 (en) * 2007-06-08 2008-12-18 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors
UY31292A1 (es) * 2007-08-14 2009-03-31 Imidazoles biciclicos fusionados
CL2008002398A1 (es) 2007-08-14 2009-07-31 Bayer Ip Gmbh Compuestos derivados de 6-(fenil piperidina) pirimidinas fusionadas con imidazol, triazol o pirozol, inhibidores de la via pi3k/akt; composicion farmaceutica; combinacion farmaceutica; y uso de los compuestos para el tratamiento de la neoplasia benigna y/o maligna y para el cancer.
EP2235019A1 (en) 2007-12-21 2010-10-06 Wyeth LLC Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
EP2303269B1 (en) 2008-06-03 2014-07-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2299825B1 (en) 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
US20110288090A1 (en) 2009-02-02 2011-11-24 Armstrong Donna J Inhibitors of AKT Activity
MA33032B1 (fr) * 2009-02-13 2012-02-01 Bayer Schering Pharma Ag Pyrimidines condensees
EP2406250B1 (en) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
WO2011033265A1 (en) 2009-09-18 2011-03-24 Almac Discovery Limited Pharmaceutical compounds
CN103097384B (zh) * 2010-07-12 2017-02-15 拜耳知识产权有限责任公司 取代的咪唑并[1,2‑a]嘧啶和吡啶
US8987273B2 (en) * 2010-07-28 2015-03-24 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-B]pyridazines
WO2012136776A1 (en) * 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors

Also Published As

Publication number Publication date
JP2014510127A (ja) 2014-04-24
PT2694510E (pt) 2016-02-08
CU20130135A7 (es) 2014-02-28
US20140113901A1 (en) 2014-04-24
DOP2013000226A (es) 2013-11-15
AU2012238589B2 (en) 2017-02-16
RS54480B1 (sr) 2016-06-30
JP5906303B2 (ja) 2016-04-20
NZ616270A (en) 2015-09-25
US9206185B2 (en) 2015-12-08
AP3597A (en) 2016-02-19
SI2694510T1 (sl) 2016-02-29
CN103596957B (zh) 2016-12-07
GT201300238A (es) 2015-04-06
PH12013502073A1 (en) 2014-01-13
CY1117163T1 (el) 2017-04-05
UA111739C2 (uk) 2016-06-10
KR20140022057A (ko) 2014-02-21
PE20141380A1 (es) 2014-10-18
SG193631A1 (en) 2013-11-29
EA201301130A1 (ru) 2014-07-30
HUE026323T2 (en) 2016-05-30
CL2013002878A1 (es) 2014-05-02
AP2013007215A0 (en) 2013-10-31
ZA201307223B (en) 2014-12-23
US9604989B2 (en) 2017-03-28
MX2013011699A (es) 2014-01-31
MA35016B1 (fr) 2014-04-03
EP2694510A1 (en) 2014-02-12
AU2012238589A1 (en) 2013-11-07
EP2694510B1 (en) 2015-10-14
CO6862145A2 (es) 2014-02-10
UY34006A (es) 2012-10-31
ME02316B (me) 2016-06-20
HRP20160011T1 (hr) 2016-02-12
PL2694510T3 (pl) 2016-03-31
JO3068B1 (ar) 2017-03-15
CU24263B1 (es) 2017-07-04
ES2558780T3 (es) 2016-02-08
TW201245204A (en) 2012-11-16
CR20130515A (es) 2013-12-04
CN103596957A (zh) 2014-02-19
US20150368250A1 (en) 2015-12-24
TN2013000400A1 (en) 2015-03-30
BR112013025777A2 (pt) 2016-12-20
DK2694510T3 (en) 2016-01-18
IL228567A0 (en) 2013-12-31
WO2012136776A1 (en) 2012-10-11
AR087148A1 (es) 2014-02-26
MX336865B (es) 2016-02-04
CA2832374A1 (en) 2012-10-11
SMT201600001B (it) 2016-02-25
NI201300105A (es) 2014-07-14
EA024890B1 (ru) 2016-10-31
TWI535719B (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
ECSP13013008A (es) Imidazopiridazinas como inhibidores de quinasa akt
UY34092A (es) Nuevos compuestos como inhibidores de jak
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34648A (es) Amidas como inhibidores de pim
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
UY34104A (es) ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
UY34212A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY34472A (es) Derivados modificados de 4-fenil-piridina
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34108A (es) ?proceso para la fabricación de sustratos revestidos?.
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
UY34318A (es) ?derivados de isotiazolina útiles como compuestos insecticidas?
UY33930A (es) Inhibidores novedosos de quinasas
GT201300078A (es) Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion
UY34034A (es) Triazolopiridinas
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
NZ711192A (en) Process for making benzoxazepin compounds
UY33976A (es) Derivados de pirazolo-pirimidina.